Bluebird Bio Earnings Reports

Bluebird Bio's Q3 2024 net revenue was $10.6 million. Patient starts more than doubled from Q2 to Q3. The company is focused on securing additional cash resources to extend its runway and reach cash flow break-even in the second half of 2025.

Bluebird Bio reported a first quarter net revenue of $18.6 million. The company completed the first patient start for LYFGENIA and anticipates 85 to 105 patient starts across its portfolio in 2024. They expect their cash and cash equivalents to be sufficient to meet planned operating expenses and capital expenditure requirements through Q1 2026.

Bluebird Bio reported Q4 2023 revenue of $7.8 million and full year 2023 revenue of $29.5 million. The company anticipates 85 to 105 patient starts across its three FDA approved therapies in 2024. They also announced a $175 million term loan facility with Hercules Capital, extending the cash runway through Q1 2026.

Bluebird Bio reported a net revenue of $12.4 million for Q3 2023, primarily driven by SKYSONA and ZYNTEGLO product revenue. The company's cash, cash equivalents, marketable securities, and restricted cash balance was approximately $227 million as of September 30, 2023. They anticipate full-year 2023 net cash burn to be in the range of $270-$300 million.

Bluebird Bio reported a net loss of $72.9 million for the second quarter of 2023. The company's cash, cash equivalents, marketable securities, and restricted cash balance was approximately $291 million as of June 30, 2023. Total revenue, net was $6.9 million for the three months ended June 30, 2023.

Bluebird Bio reported a net income of $21.2 million for the first quarter of 2023, compared to a net loss of $122.2 million for the same period in 2022. The company's cash, cash equivalents, marketable securities, and restricted cash balance was approximately $364 million as of March 31, 2023. First commercial infusions were completed for both ZYNTEGLO® and SKYSONA®.

Bluebird Bio reported its Q4 and full year 2022 financial results, highlighting commercial launch progress for ZYNTEGLO® and SKYSONA®, and provided an update on the lovo-cel BLA submission for sickle cell disease.

Bluebird Bio's Q3 2022 saw the commercial launch of ZYNTEGLO, FDA approval of SKYSONA, and the appointment of a new CFO. The company is on track for its first apheresis in Q4 2022 and anticipates commercial readiness for SKYSONA in the same quarter. Financial guidance was adjusted to account for increased launch investments. The company ended the quarter with $186M in cash, cash equivalents, marketable securities, and restricted cash.

Bluebird Bio reported significant progress in the second quarter, with unanimous FDA advisory committee support for beti-cel and eli-cel. The company is focused on commercial readiness and anticipates launching both therapies in the fourth quarter of this year. The BLA submission for lovo-cel remains on track for the first quarter of next year.

Bluebird Bio reported a net loss of $122.2 million for the first quarter of 2022, with total revenue of $1.9 million. The company is restructuring to reduce operating costs and expects full-year 2022 cash burn to be less than $340 million. They ended the quarter with $312 million in restricted cash, cash equivalents, and marketable securities.

Bluebird Bio reported fourth-quarter financial results, highlighting the ongoing review of their gene therapies, beti-cel and eli-cel, by the FDA, and the planned BLA submission for lovo-cel in Q1 2023. The company ended the year with $442 million in restricted cash, cash equivalents, and marketable securities.

Bluebird Bio reported total revenues of $22.7 million for the third quarter ended September 30, 2021, compared to $19.3 million for the three months ended September 30, 2020. Net loss was $216.8 million for the three months ended September 30, 2021, compared to $194.7 million for the three months ended September 30, 2020. As of September 30, 2021, cash, cash equivalents and marketable securities were $970.7 million.

Bluebird Bio reported a net loss of $241.7 million for the second quarter of 2021, with total revenues of $7.5 million. The company is on track to complete its business separation in the fourth quarter of 2021 and is focusing its severe genetic disease (SGD) business on the U.S. market. The FDA has placed a clinical hold on studies of elivaldogene autotemcel (eli-cel) following a safety report.

Bluebird Bio reported its Q1 2021 financial results, featuring the FDA approval of Abecma and progress in resolving safety events in their sickle cell disease program. The company is also advancing its planned business separation, targeted for completion by year-end 2021.

Bluebird Bio reported Q4 2020 financial results, with total revenues increasing slightly to $10.7 million compared to $10.0 million in Q4 2019. The company experienced a net loss of $199.9 million, a slight improvement from the $223.3 million loss in the same period of the previous year. The report highlights the first commercial infusion of ZYNTEGLO in Germany and updates on clinical holds and business separation plans.

Bluebird Bio reported a net loss of $194.7 million on revenues of $19.3 million for the third quarter of 2020. The company is advancing its cell and gene therapy programs and anticipates multiple approvals in the U.S. and EU.

Bluebird Bio reported its Q1 2020 financial results, highlighting an agreement with the FDA on the regulatory path for LentiGlobin for sickle cell disease and the submission of the ide-cel BLA with Bristol Myers Squibb. The company also amended its BMS collaboration, securing $200 million, and revised its operating plan to achieve over $500 million in cash savings through 2022, extending its cash runway into 2022.

Bluebird Bio reported fourth-quarter financial results, with collaboration and license and royalty revenues of $10.0 million and a net loss of $223.3 million. The company ended the quarter with $1.24 billion in cash, cash equivalents, and marketable securities, and made significant progress in its clinical programs, including the launch of ZYNTEGLO in Germany and positive data from the KarMMa study.